OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

ABSTRACT:

Background

Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result. Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy. The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS. Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.

Methods and findings

Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet need

SUBMITTER: Matsumoto M 

PROVIDER: S-EPMC1664607 | biostudies-literature | 2006 Nov

REPOSITORIES: biostudies-literature